Section 661.210  Blood Spot Reporting

Any medical care facility or health care provider submitting newborn screening specimens to the Illinois Department of Public Health Laboratory shall comply with all requirements of this Part, and shall notify the Department immediately whenever further testing on a newborn that was performed by the medical care facility or another outside laboratory indicates that:

a)         phenylalanine levels are abnormal;

b)         T4 determinations are abnormal or TSH determinations are abnormal;

c)         total galactose or galactose-1-phosphate uridyl transferase determinations are abnormal;

d)         17-hydroxyprogesterone determinations are abnormal;

e)         biotinidase enzyme determinations are abnormal;

f)         abnormal hemoglobin patterns are identified;

g)         abnormal amino acid or acylcarnitine patterns have been identified;

h)         abnormal determinations that may indicate cystic fibrosis have been identified;

i)          abnormal determinations that may indicate a lysosomal storage disorder have been identified;

j)          abnormal determinations that may indicate severe combined immunodeficiency or T cell lymphopenia have been identified;

k)         abnormal determinations that may indicate adrenoleukodystrophy have been identified; or

l)          abnormal determinations that may indicate spinal muscular atrophy have been identified.